Clinical Utility of Cell-free and Circulating Tumor DNA in Kidney and Bladder Cancer: A Critical Review of Current Literature

Lo, 1997, Presence of fetal DNA in maternal plasma and serum, Lancet, 350, 485, 10.1016/S0140-6736(97)02174-0 Burnham, 2018, Urinary cell-free DNA is a versatile analyte for monitoring infections of the urinary tract, Nat Commun, 9, 2412, 10.1038/s41467-018-04745-0 Margraf, 2008, Neutrophil-derived circulating free DNA (cf-DNA/NETs): a potential prognostic marker for posttraumatic development of inflammatory second hit and sepsis, Shock, 30, 352, 10.1097/SHK.0b013e31816a6bb1 Leon, 1977, Free DNA in the serum of cancer patients and the effect of therapy, Cancer Res, 37, 646 Jahr, 2001, DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells, Cancer Res, 61, 1659 Jiang, 2016, The long and short of circulating cell-free DNA and the ins and outs of molecular diagnostics, Trends Genet, 32, 360, 10.1016/j.tig.2016.03.009 Bronkhorst, 2016, Characterization of the cell-free DNA released by cultured cancer cells, Biochim Biophys Acta, 1863, 157, 10.1016/j.bbamcr.2015.10.022 Anker, 1975, Spontaneous release of DNA by human blood lymphocytes as shown in an in vitro system, Cancer Res, 35, 2375 Bettegowda, 2014, Detection of circulating tumor DNA in early- and late-stage human malignancies, Sci Transl Med, 6, 10.1126/scitranslmed.3007094 Diehl, 2008, Circulating mutant DNA to assess tumor dynamics, Nat Med, 14, 985, 10.1038/nm.1789 Bacon, 2020, Plasma circulating tumor DNA and clonal hematopoiesis in metastatic renal cell carcinoma, Clin Genitourin Cancer, 18, 10.1016/j.clgc.2019.12.018 Jensen, 2021, Association of clonal hematopoiesis in DNA repair genes with prostate cancer plasma cell-free DNA testing interference, JAMA Oncol, 7, 107, 10.1001/jamaoncol.2020.5161 Siravegna, 2017, Integrating liquid biopsies into the management of cancer, Nat Rev Clin Oncol, 14, 531, 10.1038/nrclinonc.2017.14 Postel, 2018, Droplet-based digital PCR and next generation sequencing for monitoring circulating tumor DNA: a cancer diagnostic perspective, Expert Rev Mol Diagn, 18, 7, 10.1080/14737159.2018.1400384 Zviran, 2020, Genome-wide cell-free DNA mutational integration enables ultra-sensitive cancer monitoring, Nat Med, 26, 1114, 10.1038/s41591-020-0915-3 Elazezy, 2018, Techniques of using circulating tumor DNA as a liquid biopsy component in cancer management, Comput Struct Biotechnol J, 16, 370, 10.1016/j.csbj.2018.10.002 Garcia-Murillas, 2015, Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer, Sci Transl Med, 7, 10.1126/scitranslmed.aab0021 Chaudhuri, 2017, Early detection of molecular residual disease in localized lung cancer by circulating tumor DNA profiling, Cancer Discov, 7, 1394, 10.1158/2159-8290.CD-17-0716 Sausen, 2015, Clinical implications of genomic alterations in the tumour and circulation of pancreatic cancer patients, Nat Commun, 6, 7686, 10.1038/ncomms8686 McGranahan, 2017, Clonal heterogeneity and tumor evolution: past, present, and the future, Cell, 168, 613, 10.1016/j.cell.2017.01.018 Jamal-Hanjani, 2015, Translational implications of tumor heterogeneity, Clin Cancer Res, 21, 1258, 10.1158/1078-0432.CCR-14-1429 Adalsteinsson, 2017, Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors, Nat Commun, 8, 1324, 10.1038/s41467-017-00965-y Zill, 2015, Cell-free DNA next-generation sequencing in pancreatobiliary carcinomas, Cancer Discov, 5, 1040, 10.1158/2159-8290.CD-15-0274 Schrock, 2018, Hybrid capture–based genomic profiling of circulating tumor DNA from patients with advanced cancers of the gastrointestinal tract or anus, Clin Cancer Res, 24, 1881, 10.1158/1078-0432.CCR-17-3103 Corcoran, 2018, Application of cell-free DNA analysis to cancer treatment, N Engl J Med, 379, 1754, 10.1056/NEJMra1706174 Lanman, 2015, Analytical and clinical validation of a digital sequencing panel for quantitative, highly accurate evaluation of cell-free circulating tumor DNA, PLoS One, 10, 10.1371/journal.pone.0140712 Malapelle, 2017, Profile of the Roche cobas® EGFR mutation test v2 for non-small cell lung cancer, Expert Rev Mol Diagn, 17, 209, 10.1080/14737159.2017.1288568 Babjuk, 2019, European Association of Urology guidelines on non-muscle-invasive bladder cancer (TaT1 and carcinoma in situ)—2019 update, Eur Urol, 76, 639, 10.1016/j.eururo.2019.08.016 Vandekerkhove, 2017, Circulating tumor DNA reveals clinically actionable somatic genome of metastatic bladder cancer, Clin Cancer Res, 23, 6487, 10.1158/1078-0432.CCR-17-1140 Barata, 2017, Next-generation sequencing (NGS) of cell-free circulating tumor DNA and tumor tissue in patients with advanced urothelial cancer: a pilot assessment of concordance, Ann Oncol, 28, 2458, 10.1093/annonc/mdx405 Chalfin, 2021, Circulating tumor cell and circulating tumor DNA assays reveal complementary information for patients with metastatic urothelial cancer, Eur Urol Oncol, 4, 310, 10.1016/j.euo.2019.08.004 Agarwal, 2018, Characterization of metastatic urothelial carcinoma via comprehensive genomic profiling of circulating tumor DNA, Cancer, 124, 2115, 10.1002/cncr.31314 Boyle, 1994, Gene mutations in saliva as molecular markers for head and neck squamous cell carcinomas, Am J Surg, 168, 429, 10.1016/S0002-9610(05)80092-3 Sidransky, 1992, Identification of ras oncogene mutations in the stool of patients with curable colorectal tumors, Science, 256, 102, 10.1126/science.1566048 Kinde, 2013, Evaluation of DNA from the Papanicolaou test to detect ovarian and endometrial cancers, Sci Transl Med, 5, 10.1126/scitranslmed.3004952 Botezatu, 2000, Genetic analysis of DNA excreted in urine: a new approach for detecting specific genomic DNA sequences from cells dying in an organism, Clin Chem, 46, 1078, 10.1093/clinchem/46.8.1078 Dudley, 2019, Detection and surveillance of bladder cancer using urine tumor DNA, Cancer Discov, 9, 500, 10.1158/2159-8290.CD-18-0825 Birkenkamp-Demtröder, 2016, Genomic alterations in liquid biopsies from patients with bladder cancer, Eur Urol, 70, 75, 10.1016/j.eururo.2016.01.007 Kompier, 2010, FGFR3, HRAS, KRAS, NRAS and PIK3CA mutations in bladder cancer and their potential as biomarkers for surveillance and therapy, PLoS One, 5, 10.1371/journal.pone.0013821 Christensen, 2017, Liquid biopsy analysis of FGFR3 and PIK3CA hotspot mutations for disease surveillance in bladder cancer, Eur Urol, 71, 961, 10.1016/j.eururo.2016.12.016 Soave, 2017, Copy number variations of circulating, cell-free DNA in urothelial carcinoma of the bladder patients treated with radical cystectomy: a prospective study, Oncotarget, 8, 56398, 10.18632/oncotarget.17657 Grivas, 2020, Circulating tumor DNA alterations in advanced urothelial carcinoma and association with clinical outcomes: a pilot study, Eur Urol Oncol, 3, 695, 10.1016/j.euo.2019.02.004 Patel, 2017, Association of plasma and urinary mutant DNA with clinical outcomes in muscle invasive bladder cancer, Sci Rep, 7, 5554, 10.1038/s41598-017-05623-3 Birkenkamp-Demtröder, 2018, Monitoring treatment response and metastatic relapse in advanced bladder cancer by liquid biopsy analysis, Eur Urol, 73, 535, 10.1016/j.eururo.2017.09.011 Christensen, 2019, Early detection of metastatic relapse and monitoring of therapeutic efficacy by ultra-deep sequencing of plasma cell-free DNA in patients with urothelial bladder carcinoma, J Clin Oncol, 37, 1547, 10.1200/JCO.18.02052 Pal, 2020, Infigratinib in upper tract urothelial carcinoma versus urothelial carcinoma of the bladder and its association with comprehensive genomic profiling and/or cell-free DNA results, Cancer, 126, 2597, 10.1002/cncr.32806 Pal, 2018, Efficacy of BGJ398, a fibroblast growth factor receptor 1-3 inhibitor, in patients with previously treated advanced urothelial carcinoma with FGFR3 alterations, Cancer Discov, 8, 812, 10.1158/2159-8290.CD-18-0229 Andius, 2007, Prognostic factors in stage T1 bladder cancer: tumor pattern (solid or papillary) and vascular invasion more important than depth of invasion, Urology, 70, 758, 10.1016/j.urology.2007.06.638 Feng, 2013, Quantification of plasma cell-free DNA in predicting therapeutic efficacy of sorafenib on metastatic clear cell renal cell carcinoma, Dis Markers, 34, 105, 10.1155/2013/651323 Wan, 2013, Monitoring of plasma cell-free DNA in predicting postoperative recurrence of clear cell renal cell carcinoma, Urol Int, 91, 273, 10.1159/000351409 Skrypkina, 2016, Concentration and methylation of cell-free DNA from blood plasma as diagnostic markers of renal cancer, Dis Markers, 2016, 10.1155/2016/3693096 de Martino, 2012, Serum cell-free DNA in renal cell carcinoma: a diagnostic and prognostic marker, Cancer, 118, 82, 10.1002/cncr.26254 Lu, 2016, Diagnostic and prognostic potential of circulating cell-free genomic and mitochondrial DNA fragments in clear cell renal cell carcinoma patients, Clin Chim Acta, 452, 109, 10.1016/j.cca.2015.11.009 Cristiano, 2019, Genome-wide cell-free DNA fragmentation in patients with cancer, Nature, 570, 385, 10.1038/s41586-019-1272-6 Alcaide, 2020, Evaluating the quantity, quality and size distribution of cell-free DNA by multiplex droplet digital PCR, Sci Rep, 10, 12564, 10.1038/s41598-020-69432-x Lasseter, 2020, Plasma cell-free DNA variant analysis compared with methylated DNA analysis in renal cell carcinoma, Genet Med, 22, 1366, 10.1038/s41436-020-0801-x Nuzzo, 2020, Detection of renal cell carcinoma using plasma and urine cell-free DNA methylomes, Nat Med, 26, 1041, 10.1038/s41591-020-0933-1 Yamamoto, 2019, Clinical significance of the mutational landscape and fragmentation of circulating tumor DNA in renal cell carcinoma, Cancer Sci, 110, 617, 10.1111/cas.13906 Zill, 2018, The landscape of actionable genomic alterations in cell-free circulating tumor DNA from 21,807 advanced cancer patients, Clin Cancer Res, 24, 3528, 10.1158/1078-0432.CCR-17-3837 Hahn, 2017, Correlation of genomic alterations assessed by next-generation sequencing (NGS) of tumor tissue DNA and circulating tumor DNA (ctDNA) in metastatic renal cell carcinoma (mRCC): potential clinical implications, Oncotarget, 8, 33614, 10.18632/oncotarget.16833 Gerlinger, 2014, Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing, Nat Genet, 46, 225, 10.1038/ng.2891 Pal, 2017, Evolution of circulating tumor DNA profile from first-line to subsequent therapy in metastatic renal cell carcinoma, Eur Urol, 72, 557, 10.1016/j.eururo.2017.03.046 Maia, 2017, Association of circulating tumor DNA (ctDNA) detection in metastatic renal cell carcinoma (mRCC) with tumor burden, Kidney Cancer, 1, 65, 10.3233/KCA-170007 Jung, 2019, Cell-free SHOX2 DNA methylation in blood as a molecular staging parameter for risk stratification in renal cell carcinoma patients: a prospective observational cohort study, Clin Chem, 65, 559, 10.1373/clinchem.2018.297549 Hahn, 2019, Cell-free circulating tumor DNA (ctDNA) in metastatic renal cell carcinoma (mRCC): current knowledge and potential uses, Kidney Cancer, 3, 7, 10.3233/KCA-180048